At #AACR26, Ignacio Garrido-Laguna, MD, PhD (@GarridoLagunaMD) serves as discussant for the Clinical Trials Plenary, offering expert perspective on early findings from a first-in-human Phase 1 study of the anti-CCR8 antibody denikitug in advanced solid tumors. #MoffittAACR26 https://t.co/axxgs7UOYo